ARCHIVES

NIH institute directors, in response to question from Sen. Arlen Specter, say Bush Administration’s stem cell research policy is harmful to NIH leadership in science.

This article is from The Cancer Letter archive.

Vol. 31 No. 14 | April 8, 2005

Download PDF Visit The Full Archive

Related Articles

Low-Dose Aspirin Cuts Risk Of Colorectal Growths

April 26, 2002

NCAB Committee To Propose Event Marking Cancer Act

August 2, 1991

In Brief: Curt Appointment Now Official; Bipartisan Effort Seeks $150 Million FDA Budget Increase

April 21, 1989

In Brief: Forel Retires As Dana-Farber Director, Successor Is David Livingston; Benacerraf Plans Departure

July 5, 1991

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

July 28, 1989

Also in this 8-page issue: Use cancer mortality, not 5-year survival, to track progress against cancer, researchers say.

July 29, 2005